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Neoplastic transformation of epithelial cells in whole mammary
gland in vitro
(organ culture/7,12-dimethylbenz[alanthracene/carcinogenesis/mammary cells/BALB/c mice)
NITYANAND T. TELANG, MIHIR R. BANERJEE, ANAND P. IYER, AND AMIT B. KUNDU
Tumor Biology Laboratory, School of Life Sciences, University of Nebraska, 201 Lyman Hall, Lincoln, Nebraska 68588
Communicated by James A. Miller, July 23, 1979
ABSTRACT Biological characteristics of nodule-like al-
veolar lesions (NLAL) induced by 7,12-dimethylbenz[a]an-
thracene (DMBA) in organ culture of whole mammary gland
(BALB/c female mice) were assessed after transplantation into
gland-free mammary fat pads of syngeneic virgin mice. (i)Tis-
sue-fragment explants from NLAL areas of the gland produced
abnormal lobuloalveolar (LA) outgrowths in 3 of 10 fat pads. (il)
Transplantation of dissociated cells of NLAL-derived LA out-
growths into 36 fat pads showed 100% LA outgrowths and 3
(8%) of these 36 outgrowths produced mammary carcinomas.
(iii) The explants of dissociated cells from whole mammary
glands treated with DMBA in culture produced full or partial
LA structures in 2 of 56 outgrowths. (iv) The explants of disso-
ciated cells prepared from outgrowths derived from explants
as in iii produced 9 LA outgrowths in 16 instances; mammary
tumor incidence in these outgrowths was 3 of 16 (18%). (v) The
explants of tissue fragments from LA outgrowths as in iv pro-
duced LA outgrowths in 20 of 20 fat pads; mammary carcinomas
appeared in 16 of 20 (80%) of these outgrowths. No NLAL was
detectable in control glands treated with dimethyl sulfoxide
(solvent for DMBA); explants of the control glands consistently
produced ductal outgrowths and no tumor. This accomplish-
ment of chemical carcinogen-induced neoplastic transformation
of epithelial cells in vitro provides a model for studying carci-
nogenesis in an entire isolated organ.
Use of the in vitro oncogenesis model of fibroblasts has pro-
duced impressive advances of knowledge about the patho-
genesis of neoplasia (1, 2). Attempts to obtain transformation
of epithelial cells in monolayer culture so far have been of
limited success (3-5). However, induction of neoplastic trans-
formation of cells in organ culture, in general, has remained a
challenge, although 7,12-dimethylbenz[a]anthracene
(DMBA)-induced transformation in rat mammary slices in
culture has been reported (6). Because human malignancies in
different organs are mostly of epithelial cell origin, the need
for an organ culture model for studying carcinogenesis in vitro
has been emphasized in several reports (7-9).
By using the organ culture model of the whole mammary
gland (10-14), it has been found (15-18) that treatment of the
gland in culture with hydrocarbon carcinogens (DMBA or 3-
methylcholanthrene) induces nodule-like alveolar lesions
(NLAL). DMBA also binds to DNA of the mammary cells in
culture, indicating that DMBA action in organ culture of the
whole mammary gland is consistent with the characteristics
associated with most hydrocarbon carcinogen-induced tumor-
igenesis in vivo and in vitro (2, 19). In this report we present
biological characteristics, including tumorigenesis, of mammary
epithelial cells treated with DMBA in organ culture. The
findings provide a demonstration of neoplastic transformation
of epithelial cells in culture of the whole mammary organ in
a serum-free medium.
MATERIALS AND METHODS
Animals, Organ Culture, DMBA Treatment, and NLAL
Induction. Low-mammary-tumor strain BALB/c female mice
free of mouse mammary tumor virus (MuMTV) activity were
obtained through the National Cancer Institute. The procedures
used for organ culture of the whole mammary gland, DMBA
treatment, and NLAL induction were as described (16, 18,
20).
Enzymatic Dissociation of Mammary Epithelial Cells. For
cell dissociation (CD), mammary tissue (minced) was first in-
cubated (370C) in a solution containing 1% collagenase and 1%
hyaluronidase in Waymouth's medium, and this was followed
by treatments with Pronase and DNase (21). This method of
CD yields mostly epithelial cells with about 80-90% viability
as monitored by the trypan blue exclusion test (21).
In Vivo Transplantation of NLAL and Dissociated Cells.
The biological characteristics of the mammary cells treated with
DMBA or dimethyl sulfoxide (Me2SO; solvent for DMBA) in
organ culture were determined in vivo by transplantation into
gland-free mammary fat pads of syngeneic virgin hosts ac-
cording to the standard procedure (22). Fig. 1 outlines the ex-
perimental protocol.
Examination of Outgrowths and Tumors. The outgrowths
produced by the explants in the gland-free mammary fat pads
at different times after transplantation were initially assessed
in anesthetized (Nembutal) animals injected intraperitoneally
with 0.75 ml of 0.5% trypan blue solution in 0.9% saline 24 hr
before microscopic examination. The trypan blue staining fa-
cilitates tentative detection of the outgrowth (21). As needed,
small fragments (-1 mm) of the outgrowth were transplanted
into gland-free mammary fat pads of another batch of young
hosts. The stained preparation of the fat pad was microscopi-
cally analyzed to confirm the morphological type of the out-
growth. Animals were palpated regularly for tumors; charac-
teristics of the tumors were assessed by histopathology. Growth
potential of tumor samples was tested by transplantation into
intact mammary glands (inguinal) and into subcutaneous
sites.
RESULTS
The morphology (Fig. 1) of DMBA-induced NLALs in organ
culture of the whole mammary gland was as observed earlier
(16, 18). The present experiments also showed that 70-80% of
the glands contained NLAL, with an average of eight lesions
per gland. No NLAL was observed in control glands treated
with Me2SO. A similar high incidence of DMBA-induced
NLAL in organ culture of the whole mammary gland also has
been recently observed by Tonelli et al. (24).
Abbreviations: DMBA, 7,12-dimethylbenzla lanthracene; NLAL,
nodule-like alveolar lesion; MuMTV, mouse mammary tumor virus;
CD, cell dissociation; Me2SO, dimethyl sulfoxide; Du, ductal; LADu,
mixed lobuloalveolar plus ductal; LA, lobuloalveolar; LAT, lobuloal-
veolar with tumor; HAN, hyperplastic alveolar nodule.
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FIG. 1. Experimental protocol for assessment of the biological characteristics of the mammary cells treated with DMBA in culture of the
whole mammary organ. (Series I) Whole second thoracic mammary glands of 3- to 4-week-old female BALB/c mice were cultivated for 9 days
in Waymouth's medium containing insulin, prolactin, and hydrocortisone each at 5 gg/ml and aldosterone at 1 Ag/ml. Between days 3 and 4
of culture the glands were treated for 24 hr with DMBA (7.8 MsM); control glands were treated with Me2SO (0.2% of medium). Subsequent 15-day
cultivation in medium with insulin and aldosterone caused alveolar regression, and NLALs (indicated by arrow in the photograph) were present
only in DMBA-treated glands (for details see refs. 16 and 20). One tissue fragment (fragment explant, t1 mm) from a NLAL area was transplanted
into the right gland-free inguinal mammary fat pad of a syngeneic virgin host; the left side carried the control explant. Host animals bearing
primary NLAL explants also carried a pituitary (from syngeneic male) isograft in the right kidney capsule during the initial 6 weeks after
transplantation. [Pituitary stimulation during the initial weeks is conducive to expression of transformed cells in DMBA-induced precancerous
hyperplastic alveolar nodules (HAN) of mouse mammary gland in vivo (23).] For preparation of CD explants, fat pads carrying NLAL-derived
lobuloalveolar (LA) outgrowths (see Table 1) were pooled and subjected to CD. The CD explant containing 5 X 105 cells in 10 ,l of Waymouth's
medium was then injected into one gland-free inguinal mammary fat pad of syngeneic virgin host as described (21). (Series II) The initial 9-day
cultivation and DMBA or Me2SO treatments of the glands were as in series I. Whole LA glands (as illustrated) were subjected to CD. The dis-
sociated cells contained in CD1 explants were then injected into the gland-free fat pads as in series I. For preparation of CD2 explants, the out-
growths from CD1 explants were subjected to CD. The CD2 explants containing these outgrowth cells were then injected into gland-free fat
pads as in series I.
Assessment of NLAL Explants. Table 1 shows the charac-
teristics of NLAL analyzed in series I experiments outlined in
Fig. 1. After transplantation into gland-free mammary fat pads,
fragment explants of NLAL areas produced ductal (Du), mixed
lobuloalveolar plus ductal (LADu), and lobuloalveolar (LA)
outgrowths in generation 1 (Fig. 2). Fragment explants of LA
outgrowth obtained in generation 1 and carried through serial
fat pad transplantation continued to produce LA outgrowths
(generations 2 and 3A) in virgin hosts. Fragment explants of
Me2SO-treated tissue carried in contralateral fat pads of the host
animals consistently produced only Du type outgrowth at
transplant generations 1, 2, and 3A (Fig. 2c).
Mammary fat pad transplantation of dissociated cells of
outgrowths derived from DMBA-induced hyperplastic alveolar
nodule (HAN) of mouse mammary gland in vivo has been re-
ported to elicit an enhanced expression of the latent neoplastic
cells (25, 26). In the present study, CD explants prepared from
NLAL-derived generation 2 LA outgrowths were transplanted
into 36 gland-free mammary fat pads of virgin hosts. In gen-
eration 3B all 36 CD explants produced LA outgrowths, filling
the fat pad within 8-10 weeks (Table 1). Mammary carcinomas
appeared in three of these outgrowths between 2 and 5 months
after transplantation (Fig. 3). CD explants prepared from
generation 2 outgrowths produced by fragment explants from
Me2SO-treated glands produced only Du outgrowth in con-
tralateral fat pads.
Series II
LA gland
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Table 1. Types of outgrowth derived from DMBA-induced
NLAL after mammary fat pad transplantation
Host No. of
Gener- age, fat Outgrowth type*
ation wk pads Du LADu LA LAT
it 8-48 10 5 2 3 0
2 8-48 9 0 0 9 0
3A 8-16 6 0 0 6 0
3B 8-32 36 0 0 33 3
* Du, ductal; LADu, mixed ductal and alveolar; LA, lobuloalveolar;
LAT, lobuloalveolar with tumor.
t Pituitary stimulation during the initial 6 weeks and outgrowth were
examined 10 wk after cauterization of the grafted pituitary. Gen-
eration 2 outgrowth was obtained from one of the generation 1 LA
outgrowths (the remaining two were used for whole-mount prepa-
ration). Both 3A and 3B were generation 3- outgrowths, 3A from
fragment explants and 3B from CD explants. Sixteen generation
2 LA outgrowths from a different batch of host animals were pooled
for CD (for details see Fig. 1).-Me2SO-treated cells, both in fragment
and CD explants, consistently produced only Du type outgrowth.
Assessment of CD1 Explants. Table 2 shows the results of
CD1 experiments indicated in series II of Fig. 1. Among the
total of 56 outgrowths derived from CD1 explants, 54 were Du,
1 was LADu, and 1 was LA in generation 1. Morphology of the
single LA outgrowth was essentially as illustrated in Fig. 2a.
Fragments from CDI-derived single LA outgrowth and from
the LA region of the LADu outgrowth after retransplantation
into gland-free fat pads produced similar LA outgrowth in
generation 2 (Fig. 4 a and b). Fig. 4c illustrates a typical Du
type outgrowth derived from CDI explant from Me2SO-treated
control glands.
Assessment of CD2 Explants. As outlined also in series II of
Fig.- 1, CD2 explants used in these experiments were prepared
a m _ b c _
FIG. 2. Different types of outgrowths derived from NLAL ex-
plants. (X1O.) (a) LA outgrowth ofNLAL primary explant in virgin
host 10 wk after withdrawal of pituitary stimulation. The character-
istics are typical of the outgrowth obtained in subsequent transplant
generations in virgin hosts. (b) Mixed LADu type outgrowth derived
from a primary NLAL explant. The arrow points to the LA area. (c)
Typical Du outgrowth derived from a primary explant of Me2SO-
treated gland in the contralateral fat pads.
.
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FIG. 3. Mammary tumor obtained from outgrowths of CD explant
containing cells prepared from a NLAL-derived outgrowth line.
(X200.)
from outgrowths produced by different batches of CD1 ex-
plants of DMBA-treated glands. Table 3 shows that, in experi-
ment I, three of seven CD2 explants of 2 X 105 cells produced
LA outgrowths and one of the LA outgrowths produced a
rapidly growing mammary carcinoma (of the type shown in
Fig. 3), 10 months after transplantation. In experiment II, six
of nine CD2 explants of 1 X 105 cells produced dense LA out-
growths. Mammary carcinomas appeared in two of these out-
growths 6-8 months after transplantation. In control experi-
ments, CD2 explants were prepared from outgrowths obtained
from CD1 explants of Me2SO-treated glands. The control CD2
explants in experiments I and II produced only Du outgrowths
in contralateral fat pads. In experiment III, fragment explants
from two of the LA outgrowths obtained in experiment IH were
retransplanted, one into the right and the--other into the left
gland-free fat pads of another batch of virgin hosts (Table 3).
The dense LA structure in 20 of 20 outgrowths filled the fat
pads in 8 weeks; within 4-5 months, mammary carcinomas
appeared in 16 of these 20 outgrowths (Fig. 5).
Thus, 22 mammary tumors were observed in LA outgrowths
produced by the explants of mammary cells treated with
DMBA in organ culture. The tumors were transplantable into
intact mammary gland as well as into subcutaneous sites.
Table 2. Types of outgrowth derived from CD1 explants of
DMBA-treated glands
Host No. of No. of
age, fat cells in Outgrowth type
Exp. wk pads explant Du LADu LA LAT
I 8-48 20 1 x 105 19 1 0 0
II 8-48 12 2X105 11 0 1 0
III 8-48 24 5 x 105 24 0 0 0
An average of 75-85 DMBA- or Me2SO-treated glands (36.8 mg per
gland), pooled for each CD, yielded -4.9 X 106 cells. Me2SO control
explants produced only Du type outgrowths in contralateral fat pads
(for details see Fig. 1).
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FIG. 5. Mammary adenocarcinoma in a typical hyperplastic LA
outgrowth derived from CD2 explants. (X80.)
b~i
FIG. 4. Outgrowths obtained from CD1 explants. Ln, lymph node.
(X10.) (a) LADu type mixed outgrowth. The arrow points to the LA
area. (b) LA outgrowth derived from explants of LA area of the out-
growth in a. (c) Typical Du outgrowth derived from CD1, Me2SO
control explants.
DISCUSSION
The present findings on the ability of the NLAL explants to
produce serially transplantable LA outgrowths in mammary
fat pads of virgin host strongly indicate that the nodule trans-
formation, associated with an escape of some mammary epi-
thelial cells in NLAL from "normal" hormonal control, is ir-
reversible and their characteristics appear to be similar to those
of outgrowths derived from DMBA-induced HAN of mouse
mammary gland in vivo (26, 27).
Furthermore, the appearance of several mammary tumors
in the LA outgrowths obtained from NLAL-derived CD ex-
plants clearly demonstrates that neoplastic transformation of
mammary epithelial cells is inducible by DMBA in organ cul-
ture of the whole mammary gland. The presence of latent
neoplastic cells in NLAL further suggests that at least some of
the NLAL induced in culture are potentially carcinogenic.
Normal-appearing ductal outgrowths consistently produced
by explants of Me2SO-treated glands indicate that the trans-
formation is a consequence of DMBA treatment of the mam-
mary cells in organ culture. In an earlier attempt, intact
Table 3. Different types of outgrowths produced by CD2
explants after mammary fat pad transplantation
Age of No. of
mice, fat Type of Outgrowth type
Exp. wk pads explant Du LADu LA LAT
1 8-48 7 CD2 (2X 105) 4 0 2 1
II 8-48 9 CD2 (1 x 105) 3 0 4 2
III 8-32 20 Tissue fragment 0 0 4 16
The CD1 explants used in these experiments were prepared from
batches of glands different from those in Table 2. In Exp. I and II, 16
and 12 outgrowths, respectively, produced by two different batches
ofCDl explants were used. In Exp. III, tissue fragments from the two
LA outgrowths obtained in Exp. II were transplanted into opposite
gland-free fat pads. Me2SO control explants in Exps. I and II pro-
duced only Du type outgrowth (for details see Fig. 1).
mammary gland (rat) exposed (20 min) to DMBA in culture was
found to produce mammary tumor on transplantation in vivo,
but carryover of the hydrocarbon into the site of transplantation
remained a distinct possibility in this single preliminary ex-
periment (28).
In CD1 experiments, only two explants of DMBA-treated
glands showed abnormal LA or LADu structures. The LADu
type outgrowths obtained from both NLAL and CD1 explants
appear to resemble the LADu outgrowths derived from disso-
ciated mammary cells of BALB/cfC3H (MuMTV+) female
mice (21). Fragment explants of the LA outgrowth and LA
region of the LADu outgrowth obtained from CD1 explants
produced LA outgrowth in generation 2, indicating the irre-
versible nature of the transformation. The CD1 experiments,
however, do not provide information as to whether the LA or
LADu outgrowths are derived from NLAL or non-NLAL areas
because the explants represent the total cell population of the
glands pooled. Nonetheless, the morphological characteristics
of the LA- or LADu-derived LA outgrowths appear to be
similar to those derived from NLAL explants. Because CD1
explants of Me2SO-treated glands consistently produced Du
outgrowths, LA and LADu type transformations observed in
the CD1 experiments again reflect responses of the mammary
cells to DMBA action in organ culture.
Because the CD procedure is known to favor expression of
inapparent transformed cells (21), the occurrence of LA and
LADu characteristics in only 2 of 56 outgrowths derived from
the CD1 explants appears rather low. However, recent findings
(25) have indicated that mixing CD explants of HAN cells with
dissociated normal mammary epithelial cells markedly de-
creases expression of transformed HAN cells, and the effect is
directly related to the ratio of normal to HAN cells in the
mixture. The CD1 explants in the present study are expected
to contain mostly "normal" cells because in these experiments
whole lobuloalveolar glands were used for CD (Fig. 1).
Therefore, the presence of a vast excess of "normal" mammary
cells may mask expression of the transformed cells in CD1 ex-
plants. Normal mammary cells are also known to have a finite
life expectancy, whereas nodule-transformed (HAN) mammary
cells have an unlimited proliferative potential (29). Thus, it is
conceivable that the ratio of normal to transformed cells may
be decreased during rapid spatial proliferation of the cells in
CD1 explants filling the fat pad. Consequently, explants of CD2
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5890 Medical Sciences: Telang et al.
cells may be more conducive to enhanced expression of the
transformed cells. The appearance of typical LA outgrowths
in 9 of 16 CD2 explants clearly indicates a markedly increased
expression of the latent transformed cells, apparently present
in outgrowths of CD1 explants. The expression of neoplastic
cells is also favored in outgrowths derived from CD2 explants,
as evidenced by the appearance of several mammary tumors.
Furthermore, fragment explants of CD2-derived LA out-
growths after fat pad transplantation produced mammary tu-
mors in 16 of 20 outgrowths in the following generation.
The results of the present studies demonstrate that both
nodule and tumor transformation of epithelial cells are in-
ducible by a carcinogenic chemical in culture of the whole
mammary gland. The transformation is associated with the
occurrence of discrete alveolar lesions (NLAL), some of which
produce serially transplantable LA outgrowths having tu-
morigenic potential. In this respect, the NLAL appears to be
analogous to the precancerous HAN induced by MuMTV or
carcinogenic chemicals in mouse mammary gland in vivo (26,
30). NLALs detectable within 2-3 weeks after carcinogen
treatment in culture thus may provide morphologic criteria
useful for bioassay of potential carcinogens and drugs. NLALs
are inducible also by carcinogenic aryl amines and amides (24),
and a study indicates that retinoid inhibits DMBA-induction
of these lesions (31).
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